Volume : 08, Issue : 11, November – 2021
Title:
40.CLINICAL PRESENTATIONS AND TREATMENT OUTCOMES OF CULTURE-POSITIVE BRUCELLOSIS
Authors :
Adeeb Munshi, Anas Alsuraihi, Mazin Almaghrabi, Rayan Hejazi, Nawal Almahmoudi, Enas Munshi, Faisal Al-Husayni, Mohammed Alzahrani
Abstract :
Introduction: Brucellosis is one of the most common zoonotic infections worldwide. It is an important cause of economic loss and a public health problem in many developing countries. In Saudi Arabia, the most common species is B. melitensis that causes 80 -100% of cases. In this study, we aimed to identify the clinical presentations and treatment outcomes of brucellosis.
Methodology: This is study was conducted at the King Abdulaziz Medical city, Saudi Arabia. The study included all patients that were diagnosed as culture-positive Brucella from 2000 to 2018. The data were collected from the patients’ files and electronic microbiology lab results.
Results: The study included 165 cases of culture-positive Brucella. Non-focal brucellosis was the most common presentation with a rate of 75.8%. However, brucellosis infecting the CNS was a rare presentation with only three (1.8%) patients. Doxycycline plus rifampicin was the mainstay of treatment, and 47.3% of patients received this regimen followed by streptomycin with doxycycline, which was administered to 14.5%, and 11.5% of the patients received a triple therapy including streptomycin, doxycycline, rifampicin. The improvement rate was detected among 69.7% of the patients and mortality rate of 2 cases (1.2%).
Conclusions: Brucellosis is a disease that is prevalent in our society and its prevalence has increased this decade compared to the previous one. There are different treatment regimens that can be used but the outcome is unpredictable with any choice. Doxycycline with rifampicin had the best improvement rate in our study compared to the other treatment regimens.
Key words: Brucellosis; Malta fever; Saudi Arabia; treatment; outcome.
Cite This Article:
Please cite this article in press Mohammed Alzahrani et al, Clinical Presentations and Treatment Outcomes of Culture-Positive Brucellosis., Indo Am. J. P. Sci, 2021; 08(11).
Number of Downloads : 10
References:
1. Xiang 7, Zheng W, He Y. Brucella genome annotation with literature mining and Curation. BMC Bioinformatics. 2006;7:347.
2. Kikuchi H, Kim S, Wantonable K, Watarai M. Brucella abortus D-alanyl-D-alanine carboxypeptidase contributes to its intracellular replication and resistance against nitric oxide. FEMS Microbiol Lett. 2006; 259:120–5.
3. Matyas Z, Fujikura T. Brucellosis as a world problem. Dev Biol Stand. 1984;56:3–20.
4. Bilai NE, Jamjoom GA, Bobo RA, Aly OFM, El-Nashar NM. Brucellosis in the Asir region of Saudi Arabia. Saudi Med J. 1991;12:37–41.
5. Kambal AM, Maghoub ES, Jamjoom GA, Chowdhury MNH. Brucellosis in Riyadh, Saudi Arabia: a microbiological and clinical study. Trans R Soc Trop Med Hyg. 1983:77:820–4.
6. Kiel FW, Khan MY. Analysis of 506 consecutive positive tests for brucellosis in Saudi Arabia. J Clin Microbiol. 1987;25:1384–7.
7. Bakheet HG, Alnakhli HA. Brucellosis in Saudi Arabia: Review of Literature and Epidemiology. J Trop Dis. 2019;7:304.
8. Colmenero JD, Reguera JM, Martos F, Sánchez-De-Mora D, Delgado M, Causse M, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 1996;75:195–211.
9. Aygen B, Doganay M, Sumerkan B, Yildiz O, Kayabas U. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Malad Infect. 2002;32:485–93.
10. Hasanjani Roushan MR, Mohrez M, Smailnejad Gangi SM, Soleimani Amiri MJ, Hajiahmadi M. Epidemiological features and clinical manifestations in 469 adult patients with brucellosis in Babol, Northern Iran. Epidemiol Infect. 2004;132:1109–14.
11. Bosilkovaski M, Dimzova M, Grozdanovski K. Natural history of brucellosis in an endemic region in different time periods. Acta Clin Croat. 2009;48:41–6.
12. Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997;53:245–56.
13. Young D. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. Rev Infect Dis. 1991;13:359–72.
14. Spink KW. Current status of therapy of brucellosis in human beings. J Am Med Assoc. 1960;172:697–8.
15. Solera J, Martinez-Alfaro E, Saez L. Meta-analysis of the efficacy of the combination of +rifampicin and doxycycline in the treatment of human brucellosis. Med Clin (Barc) 1994;102:731–8.
16. Ko J, Splitter GA. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev. 2003;16:65–78.
17. Ganado W, Bannister W. Bacteraemia in human brucellosis. Br Med J. 1960;1:601–3.
18. Radwan Al, Asmar JA, Frerichs WM, Bekairi SI, Al-Mukayel AA. Incidence of brucellosis in domestic livestock in Saudi Arabia. Trap Anim Health Prod. 1983;15:139–43.
19. Abdulaziz D. Aloufi, Ziad A. Memish, Abdullah M. Assiri, Scott J.N. McNabb. Trends of reported human cases of brucellosis, Kingdom of Saudi Arabia, 2004–2012. Elsevier 2015; 6(1): 11-8.
20. AA Mofleh, AIA Aska, MAA Sekait, SRA Balla, ANA Nasser, Brucellosis in Saudi Arabia: Epidemiology in the Central Region. 1996; 16(3): 349-352.